Mylan Will Remain Independent, Board Says In Rejecting Icahn Buy-Out
This article was originally published in The Pink Sheet Daily
Executive Summary
A response to Icahn's proposed $5.4 bil. bid appears to shut the door to potential "white knight" pharma company suitors that were invited through Icahn's offer. Mylan does not consider Icahn's bid "serious"; in response, High River says it would put $1.5 bil. in equity into the deal.
You may also be interested in...
ImClone Chairman Survives Icahn Ousting Threat
Icahn and two associates join company’s board, giving the billionaire one-third control.
ImClone Chairman Survives Icahn Ousting Threat
Icahn and two associates join company’s board, giving the billionaire one-third control.
Mylan Unlikely To Crown King: $3.8 Bil. Bid In Jeopardy Over Restatement
Mylan does not believe it has enough time to review King’s financial restatement and “other matters” before the Feb. 28 deadline for completing the merger. However, the company left open the possibility it could renegotiate the terms of the original acquisition agreement.